Please assess the completion status of the following clinical trial:

Trial Title: The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female able to understand and sign a witnessed informed consent,~* age ≥ 18 years~* patients with stable (Canadian Cardiovascular Society I-IV) or unstable angina pectoris (but with the most recent anginal episode occurring \>48 hours before the procedure \[provided that the most recent CK-MB mass levels are within the limits of normal\]) or documented silent ischemia~* stable hemodynamic conditions (systolic blood pressure\>100, heart rate\>40 and \<100)~* no clinical and ECG changes suggestive of ongoing acute or recent (\<48 hours) myocardial infarction.~Exclusion Criteria:~* female sex with childbearing potential~* age \<18 years~* ongoing or recent episode (\<48 hours) of unstable coronary artery disease (including both ST-elevation and non-ST-elevation acute coronary syndromes) without normalization of CK-MB mass levels~* administration of any GP IIb/IIIa inhibitors during the previous 2 weeks,~* serum creatinine \>2.5 mg/dl or \> 350 micromols/l~* ongoing serious bleeding or bleeding diathesis~* previous stroke in the last 6 months~* major surgery within the previous 6 weeks~* platelet count \<100,000 per mm3~* ejection Fraction below 30%~* known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or sensitivity to contrast which cannot be adequately pre-medicated~* hemodynamic instability (systolic blood pressure\<100 mm Hg; heart rate\<40 bpm or \>100 bpm; complex ventricular arrhythmias; atrioventricular block) requiring balloon counterpulsation or inotropic support~* simultaneous participation in another device or drug study (patient must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this study)~* positive clinical history for intracranial neoplasia, arterio-venous malformation, aneurysm~* INR ≥ 2.0 or prothrombin time 1.2 times upper limit of normality~* clinically manifested reduced liver function~* programmed surgery within one month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eptifibatide (Type: EXPERIMENTAL): Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure).
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).